[go: up one dir, main page]

ECSP12007431A - Compuestos orgánicos - Google Patents

Compuestos orgánicos

Info

Publication number
ECSP12007431A
ECSP12007431A ECSP12007431A ECSP12007431A EC SP12007431 A ECSP12007431 A EC SP12007431A EC SP12007431 A ECSP12007431 A EC SP12007431A EC SP12007431 A ECSP12007431 A EC SP12007431A
Authority
EC
Ecuador
Prior art keywords
staurosporine
benzoyl
organic compounds
warm
processes
Prior art date
Application number
Other languages
English (en)
Inventor
Pascale Hoehn
Bernd Koch
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35501294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12007431(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP12007431A publication Critical patent/ECSP12007431A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a una nueva forma cristalina II de N-benzoil-estaurosporina; a composiciones que la contienen; a procesos para su preparación; y al uso de la forma cristalina II de N-benzoil-estaurosporina en métodos de diagnóstico o en el tratamiento terapéutico de animales de sangre caliente, en especial seres humanos. La invención se refiere a las formas amorfas de N-benzoil-estaurosporina; a composiciones que las contienen; a procesos para su preparación; y al uso de la N-benzoil-estaurosporina amorfa en métodos de diagnóstico o en el tratamiento terapéutico de animales de sangre caliente, en especial seres humanos.
ECSP12007431 2004-11-05 2012-03-12 Compuestos orgánicos ECSP12007431A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62534304P 2004-11-05 2004-11-05
US64213105P 2005-01-07 2005-01-07

Publications (1)

Publication Number Publication Date
ECSP12007431A true ECSP12007431A (es) 2012-06-29

Family

ID=35501294

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12007431 ECSP12007431A (es) 2004-11-05 2012-03-12 Compuestos orgánicos

Country Status (31)

Country Link
US (2) US8198435B2 (es)
EP (3) EP2272850B1 (es)
JP (4) JP5057986B2 (es)
KR (3) KR101265850B1 (es)
CN (2) CN102627658A (es)
AR (1) AR052322A1 (es)
AU (2) AU2005300693B2 (es)
BR (1) BRPI0517689A (es)
CA (1) CA2584911C (es)
CY (1) CY1113059T1 (es)
DK (1) DK1812448T3 (es)
EC (1) ECSP12007431A (es)
ES (1) ES2388142T3 (es)
GT (1) GT200500311A (es)
HK (1) HK1211587A1 (es)
HR (1) HRP20120652T1 (es)
IL (3) IL182691A (es)
JO (1) JO2897B1 (es)
MA (1) MA29033B1 (es)
MX (2) MX2007005429A (es)
MY (2) MY154878A (es)
NO (2) NO338960B1 (es)
NZ (3) NZ599033A (es)
PE (3) PE20060947A1 (es)
PL (1) PL1812448T3 (es)
PT (1) PT1812448E (es)
RU (2) RU2394038C2 (es)
SI (1) SI1812448T1 (es)
TN (1) TNSN07165A1 (es)
TW (4) TWI433852B (es)
WO (1) WO2006048296A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660086C (en) 2006-08-16 2014-09-16 Novartis Ag Method of making solid dispersions of highly crystalline therapeutic compounds
EP2327706A1 (en) 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
KR20160008267A (ko) 2014-07-14 2016-01-22 주식회사 윈스 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템
US20200010481A1 (en) * 2017-03-06 2020-01-09 Teva Pharmaceutical Works Ltd. Solid state forms of midostaurin
WO2019215759A1 (en) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad An improved process for preparation of midostaurin
IT201900004729A1 (it) 2019-03-29 2020-09-29 Procos Spa Processo per la preparazione di midostaurina ad elevato grado di purezza
WO2020261293A1 (en) * 2019-06-24 2020-12-30 Dr. Reddy's Laboratories Limited Process for preparation of midostaurin
IT201900014346A1 (it) * 2019-08-08 2021-02-08 Procos Spa Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo
IT202000004291A1 (it) 2020-03-02 2021-09-02 Indena Spa Processo per la purificazione di alcaloidi indolo carbazolici
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2023205504A1 (en) * 2022-04-22 2023-10-26 Rutgers, The State University Of New Jersey Formulations and methods for treating epidermolysis bullosa simplex and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPS60185719A (ja) 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5073633A (en) * 1989-03-23 1991-12-17 Bristol-Myers Company BMY-41950 antitumor antibiotic
US5096330A (en) * 1990-06-21 1992-03-17 M-B-W Inc. Pitch control mechanism for a surface finishing machine
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
JPH05247955A (ja) 1992-03-06 1993-09-24 Taisei Corp 擁壁の施工方法
DE69326388T2 (de) 1992-06-22 1999-12-30 Kyowa Hakko Kogyo Co., Ltd. Verfahren zur Herstellung von Staurosporin-Derivaten
EP0763041A1 (en) * 1994-06-01 1997-03-19 Novartis AG Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
RU2191175C2 (ru) * 1995-12-11 2002-10-20 Сефалон, Инкорпорейтед Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с
JP4625603B2 (ja) * 1999-08-30 2011-02-02 ポリファー アーゲー テンプレートを固定したβヘアピンループ類似物の合成
BR0208306A (pt) 2001-03-26 2004-03-09 Novartis Ag Composições farmacêuticas
KR100407758B1 (ko) 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
WO2004094645A1 (en) 2003-04-22 2004-11-04 Lonza Ag Process for the recovery of staurosporine from a fermentation broth

Also Published As

Publication number Publication date
PE20090433A1 (es) 2009-05-05
NZ599033A (en) 2012-09-28
TWI455941B (zh) 2014-10-11
TWI530500B (zh) 2016-04-21
PE20060947A1 (es) 2006-10-30
KR20070083979A (ko) 2007-08-24
HK1108881A1 (en) 2008-05-23
MA29033B1 (fr) 2007-11-01
EP2955186A1 (en) 2015-12-16
SI1812448T1 (sl) 2012-09-28
TW201446773A (zh) 2014-12-16
HRP20120652T1 (hr) 2012-09-30
JO2897B1 (en) 2015-09-15
TNSN07165A1 (en) 2008-11-21
JP5057986B2 (ja) 2012-10-24
US20120322789A1 (en) 2012-12-20
JP2008518995A (ja) 2008-06-05
EP2272850A2 (en) 2011-01-12
IL207702A (en) 2016-09-29
EP1812448A1 (en) 2007-08-01
RU2007120695A (ru) 2008-12-10
EP1812448B1 (en) 2012-05-23
IL182691A0 (en) 2007-09-20
NO20072290L (no) 2007-05-30
CA2584911C (en) 2017-10-24
IL207702A0 (en) 2010-12-30
WO2006048296A1 (en) 2006-05-11
BRPI0517689A (pt) 2008-10-14
AU2005300693B2 (en) 2010-08-19
JP2015063569A (ja) 2015-04-09
TW201247680A (en) 2012-12-01
PL1812448T3 (pl) 2012-10-31
US8198435B2 (en) 2012-06-12
EP2272850A3 (en) 2011-09-21
MY147404A (en) 2012-11-30
KR20120101600A (ko) 2012-09-13
NZ554653A (en) 2010-10-29
RU2467012C2 (ru) 2012-11-20
RU2394038C2 (ru) 2010-07-10
MX2007005429A (es) 2007-05-18
MY154878A (en) 2015-08-14
NO340404B1 (no) 2017-04-18
CY1113059T1 (el) 2016-04-13
KR101289998B1 (ko) 2013-07-30
EP2272850B1 (en) 2017-05-10
JP2012149099A (ja) 2012-08-09
CN102627658A (zh) 2012-08-08
HK1211587A1 (en) 2016-05-27
PT1812448E (pt) 2012-08-24
TWI530501B (zh) 2016-04-21
NO338960B1 (no) 2016-11-07
RU2009137788A (ru) 2011-04-20
TW201247681A (en) 2012-12-01
KR101333851B1 (ko) 2013-11-27
KR101265850B1 (ko) 2013-05-20
ES2388142T3 (es) 2012-10-09
TW200628474A (en) 2006-08-16
JP2017061578A (ja) 2017-03-30
NO20161152A1 (no) 2007-05-30
IL217571A (en) 2017-07-31
CN102993213A (zh) 2013-03-27
IL182691A (en) 2013-02-28
GT200500311A (es) 2006-05-22
MX346525B (es) 2017-03-23
KR20120101601A (ko) 2012-09-13
AU2009245817B2 (en) 2013-02-21
DK1812448T3 (da) 2012-08-27
JP5701246B2 (ja) 2015-04-15
US20090137552A1 (en) 2009-05-28
PE20130377A1 (es) 2013-04-03
AU2005300693A1 (en) 2006-05-11
AU2009245817A1 (en) 2009-12-24
CA2584911A1 (en) 2006-05-11
NZ588025A (en) 2012-04-27
US8710216B2 (en) 2014-04-29
AR052322A1 (es) 2007-03-14
TWI433852B (zh) 2014-04-11

Similar Documents

Publication Publication Date Title
ECSP12007431A (es) Compuestos orgánicos
UY30728A1 (es) Sales y formas de cristal del 2-metil-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il-fenil]propionitrilo
HN2008000311A (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
CL2006001266A1 (es) Formas solidas cristalinas i, ii, iii, iv y v de tigeciclina; procedimiento de preparacion de las formas cristalinas ii, iv y v; composicion farmaceutica que comprende las formas cristalinas; y su uso para tratar infecciones bacterianas.
CR10091A (es) Compuestos orgánicos
HN2004000490A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
MX2008005853A (es) Mezclas insecticidas sinergicas para el tratamiento de las semillas
HN2012001162A (es) Triazolopiridinas
GT200600346A (es) Nueva fórmula cristalina v de la agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
CL2011003144A1 (es) Forma cristalina e3 de bisulfato de atazanavir; composicion farmaceutica que la comprende; util para el tratamiento de enfermedades originadas por retrovirus (divisional de la solicitud 1057-05).
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
GT200500360A (es) Compuestos organicos
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
UY29170A1 (es) Adeninas sustituidas y usos de las mismas
UY29417A1 (es) Agentes endoparasiticidas
MX2010003772A (es) Forma cristalina 1 de 2-(r)-2-metilpirrolidin-2-il-1h-benzimidazol -4-carboxamida.
UY28248A1 (es) Compuestos quinicos
AR106331A2 (es) N-benzoil-estaurosporina, forma ii
ECSP109874A (es) Nuevos compuestos 892
UY30769A1 (es) Uso de epotilonas en el tratamiento de la osteoporosis y enfermedades relacionadas
ES1057646Y (es) Protesis perfeccionada para el tratamiento quirurgico de las hernias de la ingle.
CL2007002524A1 (es) Forma cristalina talfa de bromuro de (r)-3-(2-hidroxi-2,2-difenil-acetoxi)-1-(isoxazol-3-il-carbamoil-metil)-1-azonia-biciclo-[2.2.2]-octano; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso para el tratamiento de una en